DPx is the result of a $2.65 billion transaction between JLL Partners, a middle-market private equity firm, and Royal DSM, a global life sciences and materials sciences company. DPx is 51% owned by JLL Partners and 49% by Royal DSM. With headquarters in Durham, N.C., DPx’s global footprint includes 24 locations across North America, Europe, Latin America and Australia, and more than 8,000 employees.
Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units comprised of three distinct brands focused on pharmaceutical services, fine chemicals and products and proprietary technologies. These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon and Banner Life Sciences.
Pharmaceutical services will operate under the Patheon brand name and include the commercial manufacturing (CMO) capabilities, pharmaceutical product development services (PDS) and Biosolutions and Biologics (Bio) businesses of DPP. Fine Chemicals, or the ES/IM and active pharmaceutical ingredients (API) businesses, will operate under the brand name DSM Fine Chemicals. Proprietary products and technologies will operate under the Banner Life Sciences brand name.
Patheon is an end-to-end supplier providing an integrated supply chain model. Patheon delivers pharmaceutical development and manufacturing services ranging from API, biologics and biosolutions, as well as PDS and CMO capabilities. Additionally, DSM Fine Chemicals will handle complicated APIs and finished dosage forms for customers, while Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.